Loading...
Market
What will be the revenue growth of Amylyx Pharmaceuticals for Q4 2024?
3
Resolution / Starting Odds
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
Amylyx Pharmaceuticals' quarterly financial reports
Story
Amylyx Pharmaceuticals ($AMLX) Acquires Avexitide with FDA Breakthrough Therapy Designation
Jul 10, 2024, 11:04 AM
Amylyx Pharmaceuticals ($AMLX) has announced the acquisition of Avexitide, a Phase 3-ready GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation. The acquisition aims to bolster Amylyx's portfolio in blood sugar drugs, particularly for conditions such as hyperinsulinemic hypoglycemia, including post-bariatric surgery and congenital cases. The drug has supportive p2 data. The company plans to discuss the acquisition further in an upcoming conference call. The deal is seen as advantageous due to the current biotech bear market. The acquisition involves assets from Eiger ($EIGRQ).
View original story
Similar markets
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Less than 3% • 25%
3% to 4% • 25%
4% to 5% • 25%
More than 5% • 25%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Below $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
Above $12 billion • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Below $10 million • 25%
$10 million to $20 million • 25%
$20 million to $30 million • 25%
Above $30 million • 25%